Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price lifted by UBS Group from $269.00 to $315.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.
A number of other analysts also recently commented on the stock. Oppenheimer boosted their target price on shares of Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Royal Bank Of Canada reissued an “outperform” rating and set a $290.00 target price on shares of Ascendis Pharma A/S in a research note on Friday. TD Cowen raised their target price on shares of Ascendis Pharma A/S from $341.00 to $352.00 and gave the stock a “buy” rating in a report on Friday. Morgan Stanley decreased their price target on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. Finally, Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. Nineteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $313.52.
View Our Latest Report on ASND
Ascendis Pharma A/S Price Performance
Shares of NASDAQ ASND opened at $275.39 on Friday. Ascendis Pharma A/S has a twelve month low of $188.08 and a twelve month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $17.18 billion, a price-to-earnings ratio of 18.00 and a beta of 0.40. The firm has a 50-day moving average of $242.67 and a two-hundred day moving average of $239.83.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a net margin of 73.26% and a return on equity of 44.80%. As a group, analysts expect that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.
Insider Activity at Ascendis Pharma A/S
In other news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 40.00% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Ascendis Pharma A/S
Institutional investors have recently bought and sold shares of the stock. Allworth Financial LP raised its holdings in Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after buying an additional 122 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 69 shares in the last quarter. Fifth Third Bancorp lifted its stake in Ascendis Pharma A/S by 48.4% during the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 91 shares in the last quarter. Parallel Advisors LLC lifted its stake in Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 148 shares in the last quarter. Finally, IFP Advisors Inc lifted its stake in Ascendis Pharma A/S by 3,491.7% during the second quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 419 shares in the last quarter.
Ascendis Pharma A/S News Roundup
These are some of the ASND news items that stood out recently:
- Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
- Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.
- Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Further Reading
- Five stocks we like better than Ascendis Pharma A/S
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
